MORE►
Benjamin Greenberg
GenrAb CEO Larry Tiffany, who is leading the company's push to bring a first-in-class neuroprotective therapy into the clinic, also serves as Executive Chairman and Director at Medcura. [Sources: Medcura photo; iStock background; DI Studio]
UT Southwestern Spinout Emerges From Stealth With $5.6M to Push ‘First in Class’ Neuroprotective Therapy Into the Clinic
by Quincy Preston | Apr 24, 2025
Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress—the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.
